Randomised, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma
| Autor: | Markus Färkkilä, M Mäntylä, Juha Jääskeläinen, A Paetau, H Sarelin, G Blomstedt, R Raininko, P Virkkunen, M. Kallio |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Randomization Adolescent medicine.medical_treatment Gastroenterology law.invention Interferon-gamma 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Glioma medicine Humans Interferon gamma Survival analysis Aged Chemotherapy Brain Neoplasms business.industry Middle Aged medicine.disease Combined Modality Therapy Survival Analysis Recombinant Proteins 3. Good health Surgery Radiation therapy Treatment Outcome Oncology 030220 oncology & carcinogenesis Female Glioblastoma business Adjuvant 030217 neurology & neurosurgery Research Article medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.1994.263 |
| Popis: | The effect of intratumoral recombinant interferon gamma (rIFN-gamma) as adjuvant to open cytoreduction and external irradiation of 60 Gy on survival in adults with a newly diagnosed high-grade cerebral glioma was studied. The patients were randomised during surgery into the rIFN-gamma group (n = 14) or the control group (n = 17), and the latter received a subcutaneous reservoir of rIFN-gamma injections. Intratumoral rIFN-gamma was given three times a week for 4 weeks until radiotherapy, escalating the dose from 5 micrograms to 50 micrograms. Both groups received external whole-brain irradiation of 40 Gy and a local boost of 20 Gy. After radiotherapy, rIFN-gamma was continued with 50 micrograms twice a week up to 9 weeks. The patients received no chemotherapy. Intratumoral rIFN-gamma was tolerated well with transient fever only. There were 12 glioblastomas (GBs) in the control group and nine in the rIFN-gamma group with completed irradiation. The patients were followed clinically and by computerised tomography (CT) every third month until death. Tumour responses were seen in three interferon-treated (one still alive 45 months after operation) and in two conventionally treated patients. The progression of the tumour volumes on CT did not differ between the IFN-treated and control groups. There were no differences in the survival times. Median survival of the rIFN-gamma-treated patients was 54 weeks (95% CI 35-68) and of the control patients 55 weeks (95% CI 41-77). Intratumoral rIFN-gamma given in the study doses does not seem to inhibit tumour growth or improve the prognosis of patients with high-grade glioma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|